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Abstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with 
ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S® coated 
modified release formulations of mesalamine, such as Asacol®, remain among the most popular 
choices. We here review the current understanding of the mechanism of action of 5-ASA in 
inflammatory bowel disease. We evaluate evidence supporting the efficacy and safety of modified 
release mesalamine for both induction and remission maintenance in UC, including a review 
of the data from the recent ASCEND studies. We also examine the controversial issue of the 
role of mesalamine in treatment of Crohn’s disease (CD) and highlight data supporting its use 
following surgically induced remission of CD. Evidence supporting the use of mesalamine as 
prophylaxis for colorectal cancer and dysplasia will be considered. Finally, recent developments 
in our understanding of how to use modified release mesalamine in a safe and cost-effective 
manner are evaluated, including discussion of the importance of studying patient non-adherence 
as a key component of future studies in this area.
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Introduction
The therapeutic activity of 5-aminosalicyclates (5-ASA) in inflammatory bowel disease 
(IBD) was first demonstrated by the use of orally administered sulfasalazine (which is 
cleaved to its constituent 5-ASA and sulfapyridine moieties by the action of colonic 
microflora).1 While sulfasalazine is effective for induction and remission of mainte-
nance in ulcerative colitis (UC), it is poorly tolerated (particularly at higher doses). Most 
toxicity results from the sulfa component, which is largely systemically absorbed, while 
5-ASA remains predominantly in the colon.2 Indeed it was this observation that led to 
the hypothesis that 5-ASA was the active therapeutic component and this was confirmed 
in studies using enemas of the individual constituents.3 Several alternative strategies 
have been employed to direct delivery of 5-ASA to the distal intestine including the 
use of carrier molecules (as employed in the formulation of balsalazide) or the use of 
dimeric 5-ASA such as olsalazine; however arguably the more popular strategy has 
been the use of altered release formulations of mesalamine (or mesalazine), the name 
used for 5-ASA when it is employed alone as a drug. Two broad formulation strategies 
have been employed; the use of ethyl cellulose coated microgranules employed in 
the prototype prolonged release formulation Pentasa® and the use of acrylic enteric 
coating in formulations such as Asacol®, Claversal® and Salofalk®. We will here 
focus attention more specifically on Eudragit-S® coated modified release mesalamine Clinical and Experimental Gastroenterology 2009:2 140
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marketed as Asacol® or Asacolon®. We will review briefly 
data relating to the pharmacology of this preparation before 
focusing attention on studies of its use for both induction 
and remission maintenance in UC and Crohn’s disease (CD). 
We will also look at data on safety and tolerability and the 
evidence to support 5-ASA use for chemoprophylaxis of 
colorectal neoplasia. We will concentrate particular atten-
tion on recent studies and conclude with a summary of our 
views on the place of modified release mesalamine in current 
IBD therapy.
Pharmacology of modified release 
mesalamine
Modified release mesalamine (Asacol®) ensures active drug 
reaches its principal site of action in the colon by use of a 
delivery system that involves coating of the active drug in a 
synthetic polymer. The coating consists of an 80 to 130 µm 
layer of Eudragit-S®, a resin containing methacrylic acid 
and methyl methacrylic acid in a 1:2 ratio. This acrylic resin 
layer is soluble at a pH of 7 or greater, with the result that 
drug release therefore occurs in the terminal ileum, the initial 
site during transit through the gastro-intestinal tract where 
luminal pH exceed neutral. While significant variations in 
colonic 5-ASA delivery between agents have been observed, 
modified release mesalamine appears to achieve satisfactory 
concentrations of mesalamine in colonic tissue.4 Significant 
systemic 5-ASA absorption occurs with all oral prepara-
tions and absorbed mesalamine is principally inactivated by 
acetylation in the liver with subsequent urinary excretion 
of metabolites.5 Most orally administered modified release 
mesalamine is, however, excreted by the fecal route.6 The 
pharmacokinetics of delayed release mesalamines do not 
appear altered by the use of acid suppressants7 and are not 
altered significantly in patients with diarrhea.8
Mechanism of action of 5-ASA
The mechanism of action of mesalamine is far from entirely 
understood, although a growing understanding of the molecu-
lar action of 5-ASA agents has been emerging. It is now well 
established that 5-ASA drugs have effects on the production 
and action of a number of key pro-inflammatory cytokines. 
5-ASA drugs appear to impair binding of interferon-gamma 
(IFN-γ) to its receptor9 and disrupt the action of this key 
pro-inflammatory chemokine,10 including blocking of its 
detrimental effects on gut barrier function.11 5-ASA agents 
reduce ex vivo production of interleukin-1 beta (IL-1β) in 
IBD mucosal biopsies12,13 and by circulating peripheral blood 
monocytes14 and also appear to impair the production of 
interleukin 2 (IL-2) with consequent effects on proliferation of 
T-lymphocytes.15 In addition to their effects on key cytokines, 
alterations in other key mediators of inflammation have also 
been described. 5-ASA agents have been noted to have a 
significant impact on production and activity of eicosanoids 
– arachidonic acid-derived signaling molecules with important 
vascular and immunoregulatory effects. 5-aminosalicylic acid 
reduced ex vivo generation of PGE2 and LTB4 by colonic 
mucosa from UC patients in one study16 and was noted to 
reduce LTB4 in another study (where no change in PGE2 was 
detected) with an associated reduction in LTB4 to PGE2 ratio.17 
Whether these alterations are fundamental to the action of 
5-ASA (or merely co-incidental to decreased inflammation 
by other mechanisms) remains debatable.
There has been interest in the effects of mesalamine on 
free radical production, another potential mechanism for 
modulation of intestinal inflammation by these agents. 5-ASA 
may act as scavengers of superoxide free radicals produced 
by inflammatory cells18 and in some studies have shown the 
ability to abrogate oxidant induced apoptosis of intestinal 
epithelial cells, with positive associated effects on mucosal 
barrier integrity.19
Exciting recent studies have offered a more profound 
insight into the precise molecular mechanisms for the anti-
inflammatory activity of 5-ASA, namely their ability to 
activate peroxisome proliferators-activated receptor-gamma 
(PPAR-γ).20 PPARs are nuclear receptors which regulate gene 
expression. PPAR-γ is expressed at high levels in colonic 
epithelium and appears important in maintenance of mucosal 
integrity and regulation of immune activation in the intestinal 
mucosa. However, PPAR activation may only be a piece of 
the jigsaw and changes in the balance of angiogenic factors 
in a rat model of UC have now also been elucidated.21 Recent 
intriguing data have also highlighted a potential role for 
5-ASA in altering gene expression by enteric microflora,22 
a novel hypothesis which could open a new avenue in our 
understanding of the mechanism of action of these drugs.
Whatever the precise mechanism of action of these 
agents, there is abundant evidence that they exert a significant 
in vivo anti-inflammatory effect in patients with IBD. We 
will proceed therefore to review this evidence with particular 
focus on the efficacy of modified release mesalamine in a 
therapeutic setting.
Efficacy in treatment of UC
remission induction in UC
The therapeutic activity of delayed release mesalamine 
for remission induction in UC has been observed in Clinical and Experimental Gastroenterology 2009:2 141
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placebo-controlled comparisons. An initial study involved 
87 patients with mild to moderately active UC randomized 
to receive Asacol® 4.8 g/day, 1.6 g/day or placebo. Com-
plete response was observed in 24% of patients receiving 
4.8 g/day of mesalamine compared to 5% in the placebo 
group (with partial response in 50% versus 13% with placebo, 
P  0.001).23 No significant difference with placebo was 
observed for the 1.6 g/day dose, though the numbers random-
ized to this arm were small (n = 11) and the comparison was 
likely underpowered. A subsequent multi-center trial made 
a placebo-controlled comparison of modified release mesa-
lamine at two doses (2.4 g/day and 1.6 g/day) to placebo, 
with 158 patients with mild to moderate UC randomized. 
This study demonstrated significant improvement by week 6 
with both doses of mesalamine (P = 0.03 for comparison 
with 1.6 g/day dose and P = 0.003 with 2.4 g/dose), however 
only at the 2.4 g/dose was a clear difference observed in 
the proportion of patients who showed worsening (50% in 
placebo group compared to 19% with mesalamine 2.4 g/day, 
P = 0.003).24
Early comparative studies demonstrated that Eudragit 
coated mesalamine showed similar efficacy to sulfasalazine 
in patients with active UC but was better tolerated.25 Com-
parative studies followed with other 5-aminosalicylates. 
An initial randomized comparison of balsalazide 6.75 g/day 
and mesalamine 2.4 g/day in patients with active UC dem-
onstrated higher rates of complete remission at 12 weeks 
with balsalazide (62% versus 37%).26 However, a subse-
quent larger trial of 154 patients did not detect a significant 
difference in remission rates at 8 weeks between patients 
receiving balsalazide 6.75 g/day and modified release 
mesalamine 2.4 g/day.27
More recent studies of modified release mesalamine in 
active UC have focused on dose considerations, co-inciding 
with development of a new 800 mg modified release tablet 
marketed in the United States as Asacol HD®. Three studies 
have now evaluated the comparative efficacy of modified 
release mesalamine 2.4 g/day (dosed with a traditional 
400 mg Asacol® tablet) and 4.8 g/day (dosed with the new 
800 mg HD tablet). The first of these studies, ASCEND I, 
did not identify any overall difference in improvement at 
week 6 in 301 patients with mild to moderately active UC.28 
However, subgroup analysis in this study suggested an 
advantage to the higher dose specifically for patients with 
moderate (as distinct from mild) disease. The second 
study (ASCEND II) therefore focused on this subgroup 
(though patients with mild disease were still recruited).29 
In 268 patients randomized with moderately active disease 
overall improvement (defined as complete remission or 
clinical response) at week 6 was observed in 72% treated 
with mesalamine 4.8 g/day compared to 59% treated with 
the 2.4 g/day dose (P = 0.036). The results of a final study 
(ASCEND III) have recently also been reported.30 In this 
study 772 patients with moderately severe UC were ran-
domized to an identical treatment regimen with remission 
at week 6 somewhat more common in the high dose group 
(43% compared to 35%, P = 0.04), although treatment suc-
cess overall (the primary end-point) was not significantly dif-
ferent between the two groups. Interestingly, an advantage to 
high dose therapy was observed in the sub-group of patients 
previously treated for UC compared to treatment naïve/newly 
diagnosed patients. Table 1 summarizes the results of the 
principal controlled trials of the use of modified release 
mesalamine for remission induction in ulcerative colitis.
remission maintenance in UC
The efficacy of modified release mesalamine for maintenance 
of remission has also been extensively evaluated both in com-
parison with placebo and in comparisons with other 5-ASA. 
An initial multi-center study evaluated the effectiveness of 
maintenance doses of mesalamine 1.6 g/day and 0.8 g/day in 
a placebo controlled comparison.31 264 patients with UC in 
remission for 1 month were randomized with an end-point of 
endoscopic remission at 6 months defining treatment success. 
In both intention to treat and per protocol analysis mesala-
mine at both doses was significantly better than placebo for 
remission maintenance. Remission was maintained in 70.1% 
(1.6 g/day) and 63.3% (0.8 g/day) compared to 48.3% in the 
placebo group in the intention to treat analysis (P = 0.05 for 
comparison with 0.8 g/day dose, P = 0.005 for comparison 
with 1.6 g/day dose) but no significant difference between the 
two doses of mesalamine was detectable. A subsequent study 
suggested that the addition of twice weekly rectal mesalamine 
4 g to maintenance oral Asacol® 1.6 g/day significantly reduced 
the risk or relapse at one year (from 69% with oral therapy 
alone to 39% with combination treatment, P = 0.036).32
A number of studies have compared modified release 
mesalamine to sulfasalazine in maintenance therapy. Two 
early studies both showed equivalence of modified release 
mesalamine in remission maintenance in UC.33,34 A subse-
quent larger study randomized one hundred patients with a 
longer duration of follow up. This study demonstrated that 
mesalamine doses of 0.8 and 1.6 g/day were equally effec-
tive to sulfasalazine 2 to 4 g/day in remission maintenance 
with relapse rates at 48 weeks (primary end point) of 38 and 
39% respectively.35Clinical and Experimental Gastroenterology 2009:2 142
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A single randomized study has been reported which 
compared the relative efficacy of olsalazine and mesalamine.36 
One hundred patients in remission with UC were randomized 
to olsalazine 1 g/day or mesalamine (Asacol®) 1.2 g/day. 
Treatment failure at 12 months was observed in 24% in the 
olsalazine group compared to 46% in the mesalamine group 
(P = 0.025). The relapse rates observed at 1 year (only 12% 
in the olsalazine group) were less in this single center study 
than those observed in other similar comparative studies. For 
example, in a comparative multi-center study of remission 
maintenance with balsalazide (3 g/day) and modified release 
mesalamine 1.2 g/day relapse rates of 42% in both treatment 
groups were reported at 12 month follow-up.37
A recent development in technology for mesalamine 
delivery has been the development of the multimatrix system 
(MMX), a formulation system which comprises lipophilic 
and hydrophilic excipients enclosed within a pH-dependent 
coating to allow gradual release of active drug along the 
colon.38 The MMX mesalamine (Lialda®) formulation has 
demonstrated efficacy for both induction and maintenance 
in UC39,40 and results of a head to head comparison with 
modified release mesalamine for remission maintenance have 
recently been reported.41 This study randomized 331 patients 
with UC to receive either modified release mesalamine 
(Asacol®) 2.4 g/day with twice daily dosing or MMX 5-ASA 
2.4 g/day with once daily dosing with appropriate placebo 
controls in each case. The proportion of patients in clinical 
remission at 1 year was similar in both groups (66% versus 
68%) with combined rates of clinical and endoscopic remis-
sion also similar. Adverse events did not differ between the 
two study groups. The principal controlled trials for remis-
sion maintenance in UC with modified release mesalamine 
are shown in Table 2.
In summary, therefore, there is a significant body of 
evidence from randomized controlled trials of the efficacy 
of modified release mesalamine in both induction and main-
tenance of remission in UC. This agent generally appears at 
least as effective as other 5-ASA compounds at comparable 
doses. Recent developments in 5-ASA delivery technology 
have not enhanced its effectiveness compared to traditional 
5-ASA formulations, though the possibility of once daily 
dosing may impact on compliance and patient preference.
Efficacy in treatment of CD
While there is a strong general consensus about the important 
role of 5-ASA in general and mesalamine preparations in par-
ticular in the treatment of UC, the proper place of mesalamine 
in CD therapy is a much more contentious issue.
There has been only one published randomized study of 
the use of modified release mesalamine in treatment of active 
CD.42 Patients with mild to moderately active ileo-colonic CD 
were randomized to receive mesalamine 3.2 g/day (n = 20) 
Table 1 Summary of controlled trials of modified release mesalamine for induction of remission in ulcerative colitis (UC)
Study  
author
Number 
randomized
Treatment arm Comparator 
arm
Response Remission Comments
Schroeder23 n = 87 Mesalamine 4.8 g or  
1.6 g for 6 weeks
Placebo 50% (4.8 g)  
18% (1.6 g)  
13% (placebo)
24% (4.8 g)  
9% (1.6 g)  
5% (placebo)
4.8 g dose superior to placebo
Sninsky24 n = 131 Mesalamine 2.4 g or  
1.6 g for 6 weeks
Placebo 49% (2.4 g)  
43% (1.6 g)  
23% (placebo)
Per protocol analysis.  
Both doses superior to  
placebo
Green37 n = 101 Mesalamine 2.4 g  
for up to 12 weeks
Balsalazide  
6.75 g
62% (Bal)  
37% (Mes)
ABACUS induction Trial  
Balsalazide appeared superior  
to mesalamine
Levine27 n = 154 Mesalamine 2.4 g  
for 8 weeks
Balsalazide  
6.75 g  
or 2.25 g
20% (Mes)  
23% (Bal 6.75)  
19% (Bal 2.25)
No sig. difference noted  
between balsalazide 6.75 g  
and mesalamine 2.4 g
Hanauer28 n = 301 Mesalamine 4.8 g  
for 6 weeks
Mesalamine  
2.4 g
56% (4.8 g)  
51% (2.4 g)
ASCEND i includes patients  
with mild and moderate UC
Hanauer29 n = 386 Mesalamine 4.8 g  
for 6 weeks
Mesalamine  
2.4 g
72% (4.8 g)  
59% (2.4 g)
20% (4.8 g)  
18% (2.4 g)
ASCEND ii rates for n = 286  
with moderate disease only
Sandborn30 n = 772 Mesalamine 4.8 g  
for 6 weeks
Mesalamine  
2.4 g
70% (4.8 g)  
66% (2.4 g)
43% (4.8 g)  
35% (2.4 g)
ASCEND iii only patients with   
moderate disease enrolled
Abbreviations: Mes, mesalamine; Bal, balsalazide.Clinical and Experimental Gastroenterology 2009:2 143
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or placebo (n = 18). The study endpoints were remission 
(CDAI  150) or response (CDAI  150 with 70 point 
reduction from baseline) at 16 weeks. Complete response 
(remission) was observed in 45% in the treatment group 
compared to 22% in the placebo group where treatment 
failure was seen in 72% compared to 35% of the mesalamine-
treated patients.
These impressive differences have not, however, been 
reproduced by larger studies and systematic review has 
failed to identify convincing evidence for the effectiveness 
of 5-aminosalicylates for treatment of active CD.43 Indeed a 
recent meta-analysis suggested that there was no evidence 
to support the use of 5-ASA in the maintenance of medi-
cally induced remission in CD.44 However the situation may 
be somewhat different with surgically induced remission 
in CD.45 While most of the studies evaluating the use of 
mesalamine in post-operative prophylaxis have made use 
of either prolonged release (ethyl cellulose) or Eudragit-L® 
coated preparations, some of the most encouraging studies 
have evaluated the activity of Eudragit-S® coated modified 
release mesalamine (Asacol®). An initial randomized study 
of the effect of mesalamine 2.4 g/day following first intestinal 
resection for CD demonstrated a dramatic difference in both 
the rates of endoscopic recurrence and symptomatic (clinical) 
recurrence at 24 months with mesalamine.46 However the 
study has been criticized due to the absence of an adequate 
placebo control with consequent concerns about bias, 
due to inadequate allocation concealment. A subsequent 
randomized placebo controlled trial by the same authors 
evaluated the relative efficacy of modified release mesalamine 
4.0 g/day compared to 2.4 g/day when given as post-operative 
prophylaxis.47 The study (n = 101) did detect a reduction in 
the primary end-point, the number of patients with any degree 
of endoscopic recurrence (Rutgeerts score 0; 62% in the 
4.0 g group versus 46% in the 2.4 g/day group, P  0.04). 
No significant differences were detected, however, in the 
rates of severe endoscopic recurrence or clinical recurrence 
at 12 months.
A recent meta-analysis of the effectiveness of a range of 
interventions for post-operative recurrence has suggested that 
there is evidence for a modest reduction in the risk of both 
clinical and endoscopic recurrence with use of mesalamine 
preparations when used for prevention of post-operative 
CD recurrence.48 The number needed to treat to prevent a 
single clinical recurrence is 12, which raises concerns about 
the cost-effectiveness of mesalamine in this context. On the 
other hand, it can be argued that mesalamine is safe and 
well tolerated, in contrast to other agents suitable for use 
in prevention of CD recurrence. Indeed, safety issues with 
mesalamine, especially those relevant to modified release 
formulation are what we will go on to consider next.
Safety and tolerability in IBD
Data from controlled trials have showed that modified release 
mesalamine is generally well tolerated in treatment of IBD. 
A slight excess of gastro-intestinal side-effects such as 
nausea, dyspepsia and diarrhea has been reported in some 
placebo controlled trials (see Table 3) though without a 
significant dose relationship.24 However, in larger long term 
trials of modified release mesalamine dosed at 4.8 g/day 
Table 2 Summary of controlled trials of modified release mesalamine for maintenance of remission in ulcerative colitis
Study  
author
Number 
randomized
Treatment arm Comparator arm Remission Comments
Mesalamine 
Study Group31
n = 264 Mesalamine 1.6 g or  
0.8 g for 6 months
Placebo 70% (1.6 g)  
63% (0.8 g)  
48% (placebo)
intention to treat  
analysis Both doses  
superior to placebo
riley35 n = 100 Mesalamine 0.8–1.6 g  
for 48 weeks
Sulfasalazine 2–4 g 62% (Mes)  
61% (SSZ)
Treatment equivalence  
demonstrated
d’Albasio32 n = 69 Mesalamine 1.6 g with  
twice weekly 5-ASA  
enema for 12 months
Mesalamine 1.6 g 61% (combo)  
31% (oral)
Combination therapy  
superior to oral  
mesalamine alone
Courtney36 n = 100 Mesalamine 1.2 g for  
12 months
Olsalazine 1 g 54% (Mes)  
76% (Ols)
Olsalazine superior to  
mesalamine
Green37 n = 99 Mesalamine 1.2 g for  
12 months
Balsalazide 3.0 g 58% (Mes)  
58% (Bal)
Treatment equivalence  
demonstrated
Prantera41 n = 331 Mesalamine 2.4 g for  
12 months
MMX 5-ASA 2.4 g 66% (Mes)  
68% (MMX)
Treatment equivalence  
demonstrated
Abbreviations: Mes, mesalamine; Bal, balsalazide; SSZ, sulfasalazine; Ols, olsalazine; MMX, multimatrix formulation.Clinical and Experimental Gastroenterology 2009:2 144
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treatment is well tolerated with low rates of withdrawal 
due to adverse effects.29,30 Meta-analysis suggests that the 
tolerability of other 5-ASA including mesalamine is gener-
ally superior to sulfasalazine49 and that withdrawals due to 
adverse events are not significantly greater than for placebo.49 
Rare serious adverse events associated with delayed release 
mesalamine have, however, been reported including blood 
dyscrasias, pancreatitis, pneumonitis, pericarditis and 
hepatitis. A paradoxical worsening of colitis is observed 
infrequently with all 5-ASA drugs, a phenomenon that is 
not well understood. One of the most feared and contentious 
side effects of 5-ASA is the rare risk of interstitial nephritis. 
While chronic interstitial nephritis has been reported in 
association with modified release mesalamine therapy,50 
there have also been reports in IBD patients in the absence 
of 5-ASA therapy51 and both disease activity and 5-ASA 
therapy have been associated with renal tubular dysfunction 
in IBD patients.52 To date there is no evidence of any differ-
ence between 5-ASA preparations in terms of risk of renal 
dysfunction.53,54 While some authors have made recommen-
dations for close monitoring of renal function in IBD patients 
initiating 5-ASA therapy,55 this remains controversial and 
others have argued that renal dysfunction is exceptionally 
rare and that monitoring is not warranted.56
Role in chemoprophylaxis 
of colorectal neoplasia
While the principal reason for mesalamine prescribing 
remains the induction and maintenance of disease remission 
in IBD, particularly UC, there has been increasing interest 
into its potential role in prevention of neoplasia complicat-
ing chronic colitis. Few authors now dispute that there is an 
increase in the risk of colorectal cancer (CRC) in patients 
with UC and that the incidence increases progressively 
with disease duration, such that cancer risk may be as high 
as 8% by 20 years and 18% by 30 years from diagnosis of 
colitis.57 A number of epidemiological studies have sug-
gested that 5-ASA use by UC patients maybe be associated 
with a reduced incidence of CRC. A nested case control 
analysis of data from a large primary care database in the 
UK found the odds ratio (OR) of CRC was decreased in 
regular (compared to irregular) 5-ASA users (adjusted OR 
0.60, 95% confidence interval [CI] 0.38 to 0.96) and was 
negatively associated with the number of prescriptions for 
both sulfasalazine and mesalamine filled in the preceeding 
12 months.58 Another UK case control study with over 
100 cases of UC-associated CRC made similar findings 
with the OR of CRC significantly reduced with 5-ASA use, 
particularly mesalamine (OR 0.19, 95% CI 0.06 to 0.61).59 
This study also highlighted that regular clinic visits with a 
hospital doctor were also protective and there has been debate 
about whether 5-ASA use/adherence is merely a surrogate for 
better compliance with other aspects of health maintenance. 
This may partially explain the failure of some other case 
control studies to identify a significant association between 
cancer risk and preceding 5-ASA use.60 It is possible that dif-
ferences in the application of endoscopic surveillance for IBD 
associated dysplasia in different countries or geographical 
areas might influence how important an anti-neoplastic effect 
mesalamine or other 5-ASA have in a given population. The 
balance of evidence, however, appears to suggest that 5-ASA 
are protective in reducing risk of CRC but their effect on the 
incidence of dysplasia requires ongoing evaluation.61 Given 
the significant costs associated with treatment of CRC, it is 
important that the impact of 5-ASA be fully understood and 
factored into any pharmaco-economic analysis of their use. 
Indeed, this is an area that we will now go on to evaluate in 
more detail.
Recent developments in use 
of modified release mesalamine
There has been increasing focus recently on the pharmaco-
economic aspects of 5-ASA use in UC. Cost-effectiveness 
studies of 5-ASA therapies in UC have highlighted that 
both cost per flare prevented and cost per quality of life 
adjusted year (QALY) gained with maintenance 5-ASA 
treatment is substantial. It has even been suggested that 
5-ASA maintenance may only be cost-effective in the case 
of sulfasalazine (where monthly drug costs are substantially 
lower than for other 5-ASA preparations).62 However, 
healthcare costs can vary substantially both regionally 
and from country to country and so the findings of such 
studies can be difficult to apply universally. For example a 
Table 3 Common adverse effects of delayed release mesalamine 
in a large randomized placebo controlled trial24
Adverse  
effect
Placebo  Mesalamine  
1.6 g/day
Mesalamine 
2.4 g/day
vomiting 2% 2% 0%
Nausea 2% 2% 4%
Dyspepsia 0% 0% 2%
Diarrhea 0% 0% 4%
Gas 4% 2% 4%
rash 4% 4% 0%
Headache 14% 15% 4%Clinical and Experimental Gastroenterology 2009:2 145
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cost utility study performed in the UK which specifically 
examined the relative cost-effectiveness of high dose (HD) 
modified release mesalamine (4.8 g/day of Asacol HD® 
800 mg) versus standard therapy with 2.4 g/day Asacol® 
with the standard 400 mg preparation came to a very 
different conclusion.63 This analysis favored the use of 
HD mesalamine as more effective, less costly and based 
on a cost per QALY threshold of ₤30,000 reported a 72% 
likelihood that its use was cost-effective. A specific quality 
of life analysis (using the IBDQ index) on patients enrolled 
in the ASCEND I and II studies has certainly highlighted 
significant early improvements in IBDQ scores with 
modified release mesalamine therapy.64
Recent studies have also highlighted the crucial 
importance of non-adherence in the both the cost and utility 
of 5-ASA use. A recent systematic review of the impact of 
5-ASA non-adherence in UC pays particular attention to the 
cost of associated flares.65 Based on data from six 5-ASA 
RCTs they observed relative risk of flare in excess of 3.65 
in non-adherent patients. Despite the additional expenditure 
on medications in adherent patients, overall co-morbidity 
adjusted healthcare costs were greater in non-adherent 
individuals.
Given the high levels of non-compliance with maintenance 
therapy reported by UC patients,66 there has been significant 
interest in devising methods to improve adherence. 
Data on compliance in patients taking delayed release 
mesalamine have highlighted specific factors associated with 
non-compliance.67 Logistic regression revealed 3-times daily 
dosing (OR, 3.1; 95% CI, 1.8 to 8.4] and full-time employment 
(OR, 2.7; 95% CI, 1.1 to 6.9) to be independent predictors of 
non-compliance. Interestingly, clinical depression was the 
only independent predictor of complete non-compliance (OR, 
10.5; 95% CI, 1.8 to 79.0), highlighting the importance of 
identifying and treating co-morbid mood disorders in IBD 
patients in order to maximize the quality of their care. Based 
on this data, aiming for a once or twice daily dosing regime 
would certainly appear worthwhile. However, while dosing 
frequency certainly appears important other intervention may 
be considered to minimize non-adherence. Physician’s time 
spent in education and use of other simple behavioral strate-
gies may also constitute important adjuncts.68 Non-adherence 
is clearly an important issue in how 5-ASA drugs are used, 
with both significant clinical and economic consequences. 
Future studies of 5-ASA should ideally ensure that non-
adherence is included as a key outcome component.
As well as consolidating our understanding of how best 
to use mesalamine in treatment of UC and possibly in CD, 
there may be additional novel therapeutic avenues that merit 
evaluation. Future studies may be useful to examine new 
indications for mesalamine outside of IBD therapy, including 
the use of modified release mesalamine in other inflamma-
tory disorders of the colon such as diverticulitis.69 There 
has even been interest in potentially beneficial effects of the 
anti-inflammatory properties of mesalamine in functional 
bowel disorders.70
Conclusion
Modified release mesalamine (Asacol® or Asacolon®) remains 
among the most popular 5-ASA formulations currently in 
use for the treatment of IBD. There is a significant body of 
data from clinical trials that modified release mesalamine 
is more effective than placebo for both induction and 
remission maintenance in UC and this agent compares 
favorably with other 5-ASA in comparative studies. Several 
recent studies have been helpful in clarifying optimal use 
of this agent in UC. Recent data suggest that twice daily 
modified release mesalamine therapy with 4.8 g/day may 
be more effective than 2.4 g/day in remission induction in 
UC patients with disease of moderate severity, although the 
differential effect is modest at best. Recent maintenance 
studies demonstrate that at equivalent doses, twice daily 
modified release mesalamine is as effective as once daily 
MMX mesalamine. The choice between these agents is 
likely to be determined, therefore, by factors such as cost 
and patient preference. It remains to be seen, however, 
whether once daily dosing has a clinically significant advan-
tage over twice daily dosing with regards to long-term rates 
of 5-ASA compliance. There is a paucity of data to support 
mesalamine use in treatment of active CD or in maintenance 
of medically induced remission. However, there are data 
for a modest benefit for mesalamine in maintenance of 
surgically induced remission, although the number needed 
to treat to prevent a single clinical recurrence is approxi-
mately twelve. There are insufficient studies to determine 
whether any 5-ASA formulation is superior to another in 
this context. The real question is whether use of mesalamine 
is cost-effective in the post-operative setting in CD and this 
issue remains open for debate and further study. There are 
conflicting data on the cost-effectiveness of mesalamine as 
maintenance treatment for UC and this is an area that merits 
further careful evaluation. Cost-effectiveness analysis 
should probably also incorporate an understanding of the 
likely chemo preventive properties of mesalamine, as this 
may be an important consideration in how and why these 
agents are used into the future.Clinical and Experimental Gastroenterology 2009:2 146
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